NCT01966328

A Safety and Efficacy Assessment of Resolvine for Treatment of Vitreomacular Attachment

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 21 (actual)
• Sponsor: Jeffrey S Heier · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This research is studying the effect that Resolvine injection will have on patients with vitreomacular adhesion.

Detailed description

This research is studying the effect that Resolvine injection will have on patients with vitreomacular adhesion. The investigators propose that intravitreal injection of Resolvine® 36% will: 1)Result in release of the vitreous adhesion to the macula in subjects with symptomatic vitreomacular attachment (VMA). 2)The Release of the VMA will create a measurable and favorable retinal change. 3) The release of vitreomacular traction may also result in visual acuity improvement within the short time frame of this study.

Conditions

• Vitreomacular Attachment
• Vitreomacular Traction
• Vitreomacular Adhesion

Interventions

Type	Name	Description
DRUG	36% Resolvine Intravitreal Injection	36% Resolvine Intravitreal Injection
DRUG	9% Resolvine Intravitreal Injection	9% Resolvine Intravitreal Injection

Timeline

• Start date: 2013-10-01
• Primary completion: 2015-10-01
• Completion: 2015-10-01
• First posted: 2013-10-21
• Last updated: 2016-03-31

Locations

2 sites across 1 country: United States